Literature DB >> 11845895

Pseudoxanthoma elasticum: is the left internal mammary artery a suitable conduit for coronary artery bypass grafting?

Jim Iliopoulos1, Con Manganas, Nigel Jepson, David C Newman.   

Abstract

Coronary artery revascularization remains a feasible and beneficial treatment for coronary artery disease in patients with pseudoxanthoma elasticum. Careful angiographic evaluation of the left internal mammary artery and coronary arteries is required in patients with pseudoxanthoma elasticum with suspected coronary artery disease. A nonstenosed left internal mammary artery at angiography may be used as a conduit for coronary artery revascularization; however, both the effect of harvest and anastomosis on the disease process in the left internal mammary artery and the long-term patency of left internal mammary artery grafts remain unknown.

Entities:  

Mesh:

Year:  2002        PMID: 11845895     DOI: 10.1016/s0003-4975(01)03011-9

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  4 in total

1.  Arterial conduits should be evaluated preoperatively in coronary artery bypass patients with pseudoxanthoma elasticum.

Authors:  Andrew J Lodge; Leslie G Dodd; James E Lowe
Journal:  Tex Heart Inst J       Date:  2005

Review 2.  Pseudoxanthoma elasticum: a clinical, pathophysiological and genetic update including 11 novel ABCC6 mutations.

Authors:  N Chassaing; L Martin; P Calvas; M Le Bert; A Hovnanian
Journal:  J Med Genet       Date:  2005-05-13       Impact factor: 6.318

Review 3.  Pseudoxanthoma elasticum.

Authors:  Dominique P Germain
Journal:  Orphanet J Rare Dis       Date:  2017-05-10       Impact factor: 4.123

4.  The vascular phenotype in Pseudoxanthoma elasticum and related disorders: contribution of a genetic disease to the understanding of vascular calcification.

Authors:  Georges Lefthériotis; Loukman Omarjee; Olivier Le Saux; Daniel Henrion; Pierre Abraham; Fabrice Prunier; Serge Willoteaux; Ludovic Martin
Journal:  Front Genet       Date:  2013-02-12       Impact factor: 4.599

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.